AnorMED To Present At The CIBC World Markets Healthcare Conference

VANCOUVER, Nov. 8 /PRNewswire-FirstCall/ - AnorMED Inc. today announced that the Company will participate at the 16th Annual CIBC World Markets Healthcare Conference in New York City. Michael Abrams, President & CEO, will present at the conference being held at the Waldorf- Astoria on Wednesday, November 9th at 9:00am EST. Live webcasts of the presentation will be available on AnorMED's website at www.anormed.com.

About AnorMED Inc.

AnorMED is a chemistry-based biopharmaceutical company focused on the discovery, development and commercialization of new therapeutic products in the areas of hematology, HIV and oncology. AnorMEDs lead product is MOZOBIL(TM), a first in class stem cell mobilizer, is currently in a Phase III program being conducted in the U.S. for cancer patients undergoing stem cell transplant. The Company plans to complete enrollment in these studies and have 3-month follow-up by the end of 2006. To date over 581 cancer patients have been administered MOZOBIL and safety data has been reported on 191 subjects. AMD070 is the Company's lead HIV candidate currently in a Phase Ib/IIa trial being conducted in the U.S. and U.K. In the area of HIV, AnorMED has also developed a series of compounds that inhibit the CCR5 receptor, and plans to select a lead candidate for clinical studies.

AnorMED is currently traded on the American Stock Exchange and the Toronto Stock Exchange under the symbol AOM. Information on AnorMED Inc. is available on the Company's website: www.anormed.com.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update any forward-looking statements as conditions change. Investors are referred to the discussion of the risks factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated June 23, 2005.

For further information: Ms. Elisabeth Whiting, M.Sc. Kim Nelson, Ph.D. VP Corporate Development & Communications Manager, Investor Relations Tel: 604-532-4667 Tel: 604-532-4654 Cell: 604-763-4682 Cell: 604-614-2886 E-mail: ewhiting@anormed.com Email: knelson@anormed.com

CONTACT: Ms. Elisabeth Whiting, M.Sc., VP Corporate Development &Communications, Tel: (604) 532-4667, Cell: (604) 763-4682, E-mail:ewhiting@anormed.com; Kim Nelson, Ph.D., Manager, Investor Relations, Tel:(604) 532-4654, Cell: (604) 614-2886, Email: knelson@anormed.com